Table 4.
Univariate and multivariate analysis of COX-2 expression in BRAF-mutant PTC using the Cox proportional-hazards model.
| Clinical Parameters | Univariate | Multivariate | ||
|---|---|---|---|---|
| Risk Ratio (95% CI) | p-Value | Risk Ratio (95% CI) | p-Value | |
| Age | ||||
| ≥55 years (vs. <55 years) | 2.45 (1.84–3.25) | <0.0001 | 1.75 (1.22–2.48) | 0.0020 |
| Sex | ||||
| Male (vs. Female) | 0.55 (0.42–0.74) | <0.0001 | 0.52 (0.39–0.72) | <0.0001 |
| Extrathyroidal extension | ||||
| Present (vs. Absent) | 2.77 (1.96–4.01) | <0.0001 | 2.11 (1.46–3.10) | <0.0001 |
| pM | ||||
| M1 (vs. M0) | 4.69 (2.64–7.72) | <0.0001 | 4.44 (1.61–11.71) | 0.0036 |
| Stage | ||||
| IV (vs. I–III) | 3.15 (1.77–5.16) | <0.0001 | 0.49 (0.17–1.25) | 0.1656 |
| COX-2 IHC | ||||
| Overexpression (vs. low expression) | 2.10 (1.59–2.79) | <0.0001 | 2.10 (1.52–2.92) | <0.0001 |